Laevoroc Oncology, founded in 2019 and based in Zug, Switzerland, is an oncology development group pursuing an asset-centric business model through three subsidiaries. The company’s pipeline spans breakthrough innovation through to re‑imagining approved therapies across chemotherapy, immunology and neuro-oncology. Laevoroc Chemotherapy is advancing LR06, a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers. Laevoroc Immunology is progressing LR09 to treat relapse of leukemia following bone marrow transplantation, and the neuro-oncology subsidiary is building a brain-cancer pipeline that includes LR02, a first-in-class CNS ATR inhibitor. The company has acquired worldwide patents (excluding China) for an oral prodrug form of gemcitabine. Laevoroc raised over USD 1.1m in seed funding to expand operations and business reach and is actively raising Series A financing for each subsidiary.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

May 2021